About NeuMoDx
NeuMoDx is a Healthcare company based in Ann Arbor (United States) founded in 2012, and was acquired by Qiagen in September 2020. Developer of a platform for low cost molecular testing. NeuMoDx has raised $66.04 million across 5 funding rounds from investors including Qiagen, Baird Capital and Venture Investors. The company has 125 employees. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Genomics. Its legal entity is NEUMODX MOLECULAR, INC. Its competitors include DermTech, GenMark Diagnostics and Biomeme; 3 of its 3 listed competitors have raised funding.
Company details
NeuMoDx was founded in 2012 and is located in Ann Arbor, United States. A patent-pending platform for molecular testing is developed, focusing on the diagnostics sector. Magnetic particle affinity capture and real-time PCR chemistry are combined in a multi-sample microfluidic cartridge. The lead product, NeuMoDx 500, is utilized as a fully automated, random-access in vitro diagnostic system for RNA and DNA-based assays.
- Headquarters Ann Arbor, United States
- Employees 125
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website neumodx.com
- Social X
- Acquired by Qiagen (Sep 2020)
- Legal Name Neumodx Molecular, Inc
Funding Insights of NeuMoDx
NeuMoDx has successfully raised a total of $66.04M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $20.04 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $66.04M
- Total Rounds 5
- Last Round Series B — $20.04M
- First Round $5M
(Apr 2012)
- Investors Count 5
All 5 funding rounds of NeuMoDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2018 | $20.04M | Series B | – | – | – |
| Mar 2018 | $4M | Debt – Conventional | – | – | – |
| Apr 2016 | $20M | Series B | – | – | – |
| Mar 2014 | $21M | Series B | – | Pfizer Venture Investments | |
| Apr 2012 | $5M | Series A | – | Arboretum Ventures, Wolverine Venture Fund | – |
6 investors in total: 6 institutional.
Investors in NeuMoDx
NeuMoDx has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Qiagen, Baird Capital and Venture Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity and venture capital investments in B2B Tech & Services companies. | bairdcapital.com | |||
Multiple sectors focused seed & early stage VC firm investing in the US, Europe & Asia | ventureinvestors.com | Madison, United States | ||
Healthcare venture capital investments are made by Arboretum Ventures. | arboretumvc.com | Ann Arbor, United States | ||
Venture capital is focused on healthcare by Pfizer's investment arm. | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | ||
| zli.umich.edu/wolverine-venture-fund | ||||
Products and reagents for molecular diagnostic assays are supplied. | 1984 | qiagen.com | Hilden, Germany |
Investor details for NeuMoDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NeuMoDx
384 people are tracked at NeuMoDx (131 in leadership, 10 in board & advisors, 243 in team); the tracked headcount is 125.
| Name | Role | Group |
|---|---|---|
Thierry Bernard | Chief Executive Officer | Leadership |
Stephany Foster | SVP & Head, Human Resources | Leadership |
Antonio Santos | SVP & Head, Global Operations | Leadership |
Mike Evershed | Director, Project Management | Leadership |
Miriam Engels | Director, Head Of Global Talent Attraction And Acquisition | Leadership |
Bryan Burrell | Senior Sales Director | Leadership |
Christine Clarke | Senior Director, Head Of Quantiferon Sales North America | Leadership |
Jeffrey Durocher | Associate Director, Instrumentation Sales | Leadership |
Christian Houde | Senior Director Program Management, Global Operations | Leadership |
Andrew Critchley | Vp, Head Of Service Solutions EMEA And MD Qiagen Ltd | Leadership |
Danilo Oliveira | Finance Director Head For Latam | Leadership |
Thomas Fleury | Associate Director Sales Mdx | Leadership |
Kevin Gonsoulin | Sr Director, Corporate Accounts North America | Leadership |
Isabell Herrmann | Associate Director Project Management | Leadership |
Thomas Schoenig | Head Of Project Management EMEA | Leadership |
Jing Kang | Associate Director, Global Project Management | Leadership |
Daniel Gyr | Senior Director Human Resources - Head Of Labour Relations & Global HR Policies And Compliance | Leadership |
Mohammed Alsadi | Associate Director Sales Quantiferon Middle East | Leadership |
Claudia Barbosa | Global HR Learning & Development And Head Of HR Latam | Leadership |
Ralf Klingenstein | Associate Director Inside Sales | Leadership |
364 more people are available in the full profile.
Complete people profiles for NeuMoDx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NeuMoDx
4 dated milestones of NeuMoDx across 8 years, from founding to its latest funding, stage changes and deals.
- Founded NeuMoDx is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Series B, of $20.0M.
- Exit Acquired by Qiagen.
Competitors of NeuMoDx
NeuMoDx has 3 listed competitors in our database, 3 of them funded. They include DermTech, GenMark Diagnostics and Biomeme.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| dermtech.com | 1996 | San Diego, United States | $24.37M | 259 | Adhesive patch biopsies for skin cancer detection are provided. | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. | |
| biomeme.com | 2013 | Philadelphia, United States | $6.2M | 202 | Smartphone-based DNA detection platform is developed for diagnostics. |
Detailed competitors of NeuMoDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as NeuMoDx (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neumodx
Complete news archive for NeuMoDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NeuMoDx
NeuMoDx was founded in 2012.
NeuMoDx is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
NeuMoDx is a funded company, having raised a total of $66.04M across 5 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Apr 2012.
NeuMoDx has 125 employees.
NeuMoDx was founded in 2012 and is located in Ann Arbor, United States. A patent-pending platform for molecular testing is developed, focusing on the diagnostics sector. Magnetic particle affinity capture and real-time PCR chemistry are combined in a multi-sample microfluidic cartridge. The lead product, NeuMoDx 500, is utilized as a fully automated, random-access in vitro diagnostic system for RNA and DNA-based assays.
NeuMoDx's top competitors include DermTech, GenMark Diagnostics and Biomeme.
NeuMoDx has 6 investors. Key investors include Qiagen, Baird Capital, Venture Investors, Arboretum Ventures, and Pfizer Venture Investments.
NeuMoDx operates through Neumodx Molecular, Inc.
Yes. NeuMoDx was acquired by Qiagen in September 2020.